Predictive Oncology Inc. POAI Archives - Page 7 of 19

ThursdayDec 17, 2020 1:09 pm

Predictive Oncology (NASDAQ: POAI) Leverages Precision Medicine Expertise to Support Oncologists, Improve Patient Outcomes

Precision medicine is emerging approach to disease prevention, treatment that incorporates individual’s distinctive characteristics. New approach allows doctors, researchers to predict more accurately which treatments may work better. Helomics’ database, largest of its kind, is comprised of ovarian, head and neck, colon and pancreas tumors. Science has discovered that thumbprints and DNA aren’t the only biological elements that make individuals unique. In fact, ears, eyes, tongues and even the way a person walks is distinctive, unlike anybody else in the world (https://ibn.fm/SJX27). Moreover, the things that make people different from each other don’t stop at physical characteristics. Predictive Oncology (NASDAQ:…

TuesdayDec 15, 2020 2:55 pm

Using AI-Powered Models and Drug-Response Data, Predictive Oncology (NASDAQ: POAI) Holds Strong Position in Burgeoning Precision Oncology Industry

Precision oncology leverages the profile of genetic mutations in patients for the purpose of delivering precision drug-based cancer therapy Precision oncology industry forecast to be worth 99.72 billion by 2027 according to recent report POAI applies AI to proprietary data trove, aiding oncologists in personalizing cancer therapies in addition to collaborating with pharmaceutical companies for drug discovery Precision oncology is driven by the profile of genetic mutations in tumors that give practitioners required information to target therapies based off the specific mutations in the patient’s tumor. According to a recent research report, the industry is predicted to be worth 99.72…

ThursdayDec 10, 2020 12:25 pm

Predictive Oncology (NASDAQ: POAI) Releases Third-Quarter 2020 Business Update, Financial Report

Financial numbers show revenues stay level, gross margins up and operations expenses down. Company continues focus on primary mission of applying artificial intelligence to precision medicine, drug discovery. POAI subsidiaries all showing progress, growth in key areas. Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released its Q3 2020 financial report along with an update of company accomplishments and achievements (https://ibn.fm/HCpQM). In the report, POAI CEO Dr. Carl Schwartz noted milestones for each of the company’s subsidiaries: Helomics, TumorGenesis, Soluble Biotech and Skyline Medical. “Our operating cash improved…

WednesdayDec 09, 2020 1:40 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Issues Shareholder Letter Regarding Special Meeting

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today sent a letter to shareholders regarding its virtual special meeting of stockholders, originally scheduled for Dec. 1, 2020, which will be reconvened to 3 p.m. CST on Dec. 30, 2020. According to the update, POAI’s board of directors and management urge all shareholders to vote in favor of the proposals being considered at the special meeting, primarily because the reincorporation in Nevada will eliminate its obligation to pay the injurious annual Delaware franchise tax, currently equal to approximately $170,000 per…

TuesdayDec 08, 2020 1:57 pm

QualityStocksNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Solution Shaves Time, Money to Optimize Therapeutic Formulations

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. Through its subsidiary Soluble Biotech, the company delivers a solution that reduces the cost, time and manpower needed to optimize therapeutic formulations. A recent article discussing this reads, “HSC Technology is a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens, using additives and excipients commonly included in protein formulations (https://ibn.fm/QPo4W). The data generated from these screens is analyzed by a predictive algorithm used to identify the optimal combination of additives and excipients, resulting in increased…

WednesdayDec 02, 2020 10:52 am

QualityStocksNewsBreaks – Predictive Oncology (NASDAQ: POAI) Reschedules Special Stockholder Meeting, Urges Stockholder Voting

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that its virtual Special Meeting of Stockholders, which was scheduled for Dec. 1, 2020, was held but no business was conducted because a full quorum was not in attendance. The meeting has been rescheduled for Dec. 30, 2020 at 3 p.m. CST. Arrangements have been made for stockholders can attend via a live audio webcast, allowing more opportunity for stockholders to vote on proposals outlined in the definitive proxy statement filed by Predictive Oncology with the Securities and Exchange Commission…

WednesdayNov 25, 2020 11:00 am

Predictive Oncology’s (NASDAQ: POAI) Skyline Medical Sells 15 Streamway(R) Systems in Q3 2020 as COVID-era Drives Need for Sanitation Systems

Closed design of Streamway(R) System provides safety from potential hazards of drips and spills during endoscopy, radiology, cystoscopy, urology procedures The Streamway(R) System reduces costs, minimizes environmental impact of 50 million potentially disease-infected canisters disposed into landfills POAI’s Skyline Medical sells 8 Streamway(R) Systems to large university hospital in Virginia, 15 sold halfway into Q3 2020 In the age of COVID-19, the need for sanitation and safety during hospital procedures has reached an all-time high. Health professionals have reported an inhibited level of performance due to a lack of protection, comfort, and increased fatigue during surgery (https://ibn.fm/87UEr). Sanitary disposal systems,…

TuesdayNov 17, 2020 12:15 pm

QualityStocksNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Q3 Numbers, Company Updates

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released its financial results and provided business updates for the quarter ended Sept. 30, 2020. The report included a note that revenues of $0.5 million were level with the third quarter of last year, primarily driven through the sale of Predictive Oncology’s proprietary STREAMWAY product line. In addition, the company’s subsidiary, Soluble Biotech, moved into a new office and lab space and installed new equipment. POAI also signed its first contract with a pharmaceutical company for protein expression and solubility…

MondayNov 16, 2020 12:26 pm

Predictive Oncology (NASDAQ: POAI) CEO Discusses Subsidiaries’ Proprietary Tech, Innovative Media

CEO expects results that will “build the stock and raise the stock price” POAI focused on positioning TumorGenesis kits to manufacturers Helomics has largest database of its kind in the world, brings cutting-edge technology to cancer research During a recent NetworkNewsWire exclusive audio interview, Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz noted recent company milestones and outlined strategic goals. In addition, Schwartz provided key updates on the company’s four impressive subsidiaries: Skyline Medical, TumorGenesis, Soluble Biotech and Helomics. “I’m very encouraged. I think we’re moving right along. Things never go as fast as we would like them, and it can be…

ThursdayNov 12, 2020 3:30 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Poised at Convergence of AI, Cancer Care

Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company, focuses on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. The company is set to play a key role as the integration of AI technology within cancer care continues to improve the accuracy and speed of diagnosis, aid in clinical decision-making and lead to better health outcomes. A recent article discussing growing opportunity in this sector reads, “The National Cancer Institute (‘NCI’) in the United States has separately revealed that it is increasingly looking to invest in supporting research and developing infrastructure centered around the usage of…

Site Search

Company Search

Tag: Predictive Oncology Inc. POAI